NCT01160211
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01160211
Title A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | POL | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DEU | BRA | BGR | BEL | AUS | ARG

Facility Status City State Zip Country Details
Novartis Investigative Site Hollywood Florida 33021 United States Details
Novartis Investigative Site Augusta Georgia 30912 United States Details
Novartis Investigative Site Germantown Tennessee 38138 United States Details
Novartis Investigative Site Tacoma Washington 98405 United States Details
Novartis Investigative Site Berazategui Buenos Aires B1880BBF Argentina Details
Novartis Investigative Site Capital Federal Buenos Aires C1417DTN Argentina Details
Novartis Investigative Site Ciudad Autonoma de Buenos Aires Buenos Aires C1050AAK Argentina Details
Novartis Investigative Site Ciudad Autonoma de Buenos Aires Buenos Aires C1280AEB Argentina Details
Novartis Investigative Site La Plata Buenos Aires B1920CMK Argentina Details
Novartis Investigative Site Viedma Río Negro Province R8500ACE Argentina Details
Novartis Investigative Site Rosario Santa Fe Province S2000KZE Argentina Details
Novartis Investigative Site Córdoba X5004FHP Argentina Details
Novartis Investigative Site La Rioja F5300COE Argentina Details
Novartis Investigative Site Quilmes 1878 Argentina Details
Novartis Investigative Site San Miguel de Tucumán T4000IAK Argentina Details
Novartis Investigative Site Albury 2640 Australia Details
Novartis Investigative Site Douglas 4814 Australia Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Namur 5000 Belgium Details
Novartis Investigative Site Goiânia Goiás 74605-070 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande do Sul 90470-340 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande do Sul 91350-200 Brazil Details
Novartis Investigative Site Barretos São Paulo 14784-400 Brazil Details
Novartis Investigative Site São Paulo São Paulo 01317-001 Brazil Details
Novartis Investigative Site São Paulo São Paulo 03102-002 Brazil Details
Novartis Investigative Site São Paulo São Paulo 05651-901 Brazil Details
Novartis Investigative Site Rio de Janeiro 20560-120 Brazil Details
Novartis Investigative Site Plovdiv 4004 Bulgaria Details
Novartis Investigative Site Sofia 1330 Bulgaria Details
Novartis Investigative Site Sofia 1756 Bulgaria Details
Novartis Investigative Site Varna 9010 Bulgaria Details
Novartis Investigative Site Fuzhou Fujian 350001 China Details
Novartis Investigative Site Guangzhou Guangdong 510060 China Details
Novartis Investigative Site Changchun Jilin 130021 China Details
Novartis Investigative Site Harbin 150081 China Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Osijek 31000 Croatia Details
Novartis Investigative Site Zagreb 10000 Croatia Details
Novartis Investigative Site Besançon 25030 France Details
Novartis Investigative Site Montpellier 34298 France Details
Novartis Investigative Site Paris 75970 France Details
Novartis Investigative Site Munich Bavaria 81675 Germany Details
Novartis Investigative Site Fürstenwalde Brandenburg 15517 Germany Details
Novartis Investigative Site Goslar Lower Saxony 38642 Germany Details
Novartis Investigative Site Troisdorf North Rhine-Westphalia 53840 Germany Details
Novartis Investigative Site Velbert North Rhine-Westphalia 42551 Germany Details
Novartis Investigative Site Alexandroupoli 68100 Greece Details
Novartis Investigative Site Chania 73100 Greece Details
Novartis Investigative Site Heraklion 71110 Greece Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Kowloon Hong Kong Details
Novartis Investigative Site Tuenmen Hong Kong Details
Novartis Investigative Site Győr H-9024 Hungary Details
Novartis Investigative Site Gyula 5700 Hungary Details
Novartis Investigative Site Kaposvár 7400 Hungary Details
Novartis Investigative Site Miskolc 3526 Hungary Details
Novartis Investigative Site Nyíregyháza 4400 Hungary Details
Novartis Investigative Site Pécs 7624 Hungary Details
Novartis Investigative Site Szeged 6720 Hungary Details
Novartis Investigative Site Zalaegerszeg H-8900 Hungary Details
Novartis Investigative Site Nagpur 440010 India Details
Novartis Investigative Site New Delhi 110 092 India Details
Novartis Investigative Site Haifa 31096 Israel Details
Novartis Investigative Site Jerusalem 91120 Israel Details
Novartis Investigative Site Ramat Gan 52621 Israel Details
Novartis Investigative Site Rozzano (MI) Lombardy 20089 Italy Details
Novartis Investigative Site Aichi 464-8681 Japan Details
Novartis Investigative Site Chiba 277-8577 Japan Details
Novartis Investigative Site Ehime 791-0280 Japan Details
Novartis Investigative Site Osaka 537-8511 Japan Details
Novartis Investigative Site Osaka 540-0006 Japan Details
Novartis Investigative Site Saitama 362-0806 Japan Details
Novartis Investigative Site Tokyo 104-8560 Japan Details
Novartis Investigative Site Arequipa Peru Details
Novartis Investigative Site Lima Lima 18 Peru Details
Novartis Investigative Site Konin 62-500 Poland Details
Novartis Investigative Site Warsaw 04-125 Poland Details
Novartis Investigative Site Lisbon 1400-038 Portugal Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site Arkhangelsk 163045 Russia Details
Novartis Investigative Site Kazan' 420029 Russia Details
Novartis Investigative Site Moscow 115478 Russia Details
Novartis Investigative Site Ryazan 390011 Russia Details
Novartis Investigative Site Saint Petersburg 197022 Russia Details
Novartis Investigative Site Saint Petersburg 197758 Russia Details
Novartis Investigative Site Belgrade 11000 Serbia Details
Novartis Investigative Site Kamenitz 21204 Serbia Details
Novartis Investigative Site Singapore 308433 Singapore Details
Novartis Investigative Site Gyeonggi-do 10408 South Korea Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Seoul 06351 South Korea Details
Novartis Investigative Site A Coruña 15009 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Castellon 12002 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Changhua 500 Taiwan Details
Novartis Investigative Site Kaohsiung City 833 Taiwan Details
Novartis Investigative Site Taipei 11217 Taiwan Details
Novartis Investigative Site Ankara 06200 Turkey (Türkiye) Details
Novartis Investigative Site Izmir 35100 Turkey (Türkiye) Details
Novartis Investigative Site Chernivtsi 58013 Ukraine Details
Novartis Investigative Site Kharkiv 61070 Ukraine Details
Novartis Investigative Site Liutizh 07352 Ukraine Details
Novartis Investigative Site Sumy 40005 Ukraine Details
Novartis Investigative Site Uzhhorod 88000 Ukraine Details
Novartis Investigative Site Vinnitsia 21029 Ukraine Details
Novartis Investigative Site London SW3 6JJ United Kingdom Details
Novartis Investigative Site Maidstone ME16 9QQ United Kingdom Details
Novartis Investigative Site Peterborough PE3 9GZ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field